The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics
The Sonya Slifka Longitudinal Multiple Sclerosis Study follows a population-based cohort of approximately 2000 people with multiple sclerosis (MS) to study demographic and clinical characteristics, course of illness, utilization and cost of health services, provider characteristics, use of MS specia...
Gespeichert in:
Veröffentlicht in: | Multiple sclerosis 2006-02, Vol.12 (1), p.24-38 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 38 |
---|---|
container_issue | 1 |
container_start_page | 24 |
container_title | Multiple sclerosis |
container_volume | 12 |
creator | Minden, S L Frankel, D Hadden, L Perloff, J Srinath, K P Hoaglin, D C |
description | The Sonya Slifka Longitudinal Multiple Sclerosis Study follows a population-based cohort of approximately 2000 people with multiple sclerosis (MS) to study demographic and clinical characteristics, course of illness, utilization and cost of health services, provider characteristics, use of MS specialists and disease modifying agents, and neurologic, economic and psychosocial outcomes. This report describes the study methodology, presents baseline demographic and clinical data, and evaluates the representativeness of the sample. A stratified random sample of persons with established and recently-diagnosed MS selected from the National Multiple Sclerosis Society (NMSS) mailing lists was supplemented with recently-diagnosed patients recruited through systematic nationwide outreach. Baseline data were collected by computer-assisted telephone interviews derived from standardized instruments; data collection continues at six-month intervals. The cohort was comparable to population-based and clinical samples with respect to demographics, course, relapse rate, symptoms, and severity of disability. Almost two-thirds of the cohort needed help with activities of daily living, three-quarters were limited in work or other activities, and half had emotional problems that compromised quality of life. The Slifka Study cohort is broadly representative of the MS population and the database can be used to address questions not answered by natural history studies, clinical databases, or population-based surveys. |
doi_str_mv | 10.1191/135248506ms1262oa |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67635013</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1191_135248506ms1262oa</sage_id><sourcerecordid>970002711</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-9ad09ae7bbc14c4b730a440dbcc0da70be2ce3566c9c36c1d9376cbcafd378b63</originalsourceid><addsrcrecordid>eNp10E1v1DAQBmALgWgp_AAuKEKCW4odf8XcUMWXtIjDlguXaDJ2ui5OsniSw_57XO1KK4E42dI8M_a8jL0U_FoIJ94JqRvVam5GEo1pZnjELoWytubO8sflXuq10q2-YM-I7jnn1kr9lF0Io7Szwl6yn7e7UG3n6QDVNsXhF1SbebqLy-rjBKn6tqYl7lMhmEKeKVK1LbXD-2oMy272VMHkK4LxweAOMuAScqQlIj1nTwZIFF6cziv249PH25sv9eb75683HzY1SqeX2oHnDoLtexQKVW8lB6W47xG5B8v70GCQ2hh0KA0K76Q12CMMXtq2N_KKvT3O3ef59xpo6cZIGFKCKcwrdcYaqbmQBb7-C97Pay5rUteItm24lq4gcURY1qUchm6f4wj50AnePaTe_ZN66Xl1Grz2Y_DnjlPMBbw5ASCENGSYMNLZWSVba9riro-O4C6cf_f_l_8AkLCaNw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218820539</pqid></control><display><type>article</type><title>The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Minden, S L ; Frankel, D ; Hadden, L ; Perloff, J ; Srinath, K P ; Hoaglin, D C</creator><creatorcontrib>Minden, S L ; Frankel, D ; Hadden, L ; Perloff, J ; Srinath, K P ; Hoaglin, D C</creatorcontrib><description>The Sonya Slifka Longitudinal Multiple Sclerosis Study follows a population-based cohort of approximately 2000 people with multiple sclerosis (MS) to study demographic and clinical characteristics, course of illness, utilization and cost of health services, provider characteristics, use of MS specialists and disease modifying agents, and neurologic, economic and psychosocial outcomes. This report describes the study methodology, presents baseline demographic and clinical data, and evaluates the representativeness of the sample. A stratified random sample of persons with established and recently-diagnosed MS selected from the National Multiple Sclerosis Society (NMSS) mailing lists was supplemented with recently-diagnosed patients recruited through systematic nationwide outreach. Baseline data were collected by computer-assisted telephone interviews derived from standardized instruments; data collection continues at six-month intervals. The cohort was comparable to population-based and clinical samples with respect to demographics, course, relapse rate, symptoms, and severity of disability. Almost two-thirds of the cohort needed help with activities of daily living, three-quarters were limited in work or other activities, and half had emotional problems that compromised quality of life. The Slifka Study cohort is broadly representative of the MS population and the database can be used to address questions not answered by natural history studies, clinical databases, or population-based surveys.</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1191/135248506ms1262oa</identifier><identifier>PMID: 16459717</identifier><identifier>CODEN: MUSCFZ</identifier><language>eng</language><publisher>Thousand Oaks, CA: SAGE Publications</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Attitude to Health ; Biological and medical sciences ; Costs and Cost Analysis ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Demography ; Female ; Health Status ; Health Surveys ; Humans ; Immunomodulators ; Interviews as Topic ; Longitudinal Studies ; Male ; Massachusetts ; Medical sciences ; Middle Aged ; Multiple Sclerosis - diagnosis ; Multiple Sclerosis - economics ; Multiple Sclerosis - therapy ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Neurology ; Pharmacology. Drug treatments</subject><ispartof>Multiple sclerosis, 2006-02, Vol.12 (1), p.24-38</ispartof><rights>2006 INIST-CNRS</rights><rights>2006 Arnold</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c395t-9ad09ae7bbc14c4b730a440dbcc0da70be2ce3566c9c36c1d9376cbcafd378b63</citedby><cites>FETCH-LOGICAL-c395t-9ad09ae7bbc14c4b730a440dbcc0da70be2ce3566c9c36c1d9376cbcafd378b63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1191/135248506ms1262oa$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1191/135248506ms1262oa$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17438768$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16459717$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Minden, S L</creatorcontrib><creatorcontrib>Frankel, D</creatorcontrib><creatorcontrib>Hadden, L</creatorcontrib><creatorcontrib>Perloff, J</creatorcontrib><creatorcontrib>Srinath, K P</creatorcontrib><creatorcontrib>Hoaglin, D C</creatorcontrib><title>The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>The Sonya Slifka Longitudinal Multiple Sclerosis Study follows a population-based cohort of approximately 2000 people with multiple sclerosis (MS) to study demographic and clinical characteristics, course of illness, utilization and cost of health services, provider characteristics, use of MS specialists and disease modifying agents, and neurologic, economic and psychosocial outcomes. This report describes the study methodology, presents baseline demographic and clinical data, and evaluates the representativeness of the sample. A stratified random sample of persons with established and recently-diagnosed MS selected from the National Multiple Sclerosis Society (NMSS) mailing lists was supplemented with recently-diagnosed patients recruited through systematic nationwide outreach. Baseline data were collected by computer-assisted telephone interviews derived from standardized instruments; data collection continues at six-month intervals. The cohort was comparable to population-based and clinical samples with respect to demographics, course, relapse rate, symptoms, and severity of disability. Almost two-thirds of the cohort needed help with activities of daily living, three-quarters were limited in work or other activities, and half had emotional problems that compromised quality of life. The Slifka Study cohort is broadly representative of the MS population and the database can be used to address questions not answered by natural history studies, clinical databases, or population-based surveys.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Attitude to Health</subject><subject>Biological and medical sciences</subject><subject>Costs and Cost Analysis</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Demography</subject><subject>Female</subject><subject>Health Status</subject><subject>Health Surveys</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Interviews as Topic</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Massachusetts</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple Sclerosis - diagnosis</subject><subject>Multiple Sclerosis - economics</subject><subject>Multiple Sclerosis - therapy</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Neurology</subject><subject>Pharmacology. Drug treatments</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp10E1v1DAQBmALgWgp_AAuKEKCW4odf8XcUMWXtIjDlguXaDJ2ui5OsniSw_57XO1KK4E42dI8M_a8jL0U_FoIJ94JqRvVam5GEo1pZnjELoWytubO8sflXuq10q2-YM-I7jnn1kr9lF0Io7Szwl6yn7e7UG3n6QDVNsXhF1SbebqLy-rjBKn6tqYl7lMhmEKeKVK1LbXD-2oMy272VMHkK4LxweAOMuAScqQlIj1nTwZIFF6cziv249PH25sv9eb75683HzY1SqeX2oHnDoLtexQKVW8lB6W47xG5B8v70GCQ2hh0KA0K76Q12CMMXtq2N_KKvT3O3ef59xpo6cZIGFKCKcwrdcYaqbmQBb7-C97Pay5rUteItm24lq4gcURY1qUchm6f4wj50AnePaTe_ZN66Xl1Grz2Y_DnjlPMBbw5ASCENGSYMNLZWSVba9riro-O4C6cf_f_l_8AkLCaNw</recordid><startdate>20060201</startdate><enddate>20060201</enddate><creator>Minden, S L</creator><creator>Frankel, D</creator><creator>Hadden, L</creator><creator>Perloff, J</creator><creator>Srinath, K P</creator><creator>Hoaglin, D C</creator><general>SAGE Publications</general><general>Arnold</general><general>Sage Publications Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20060201</creationdate><title>The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics</title><author>Minden, S L ; Frankel, D ; Hadden, L ; Perloff, J ; Srinath, K P ; Hoaglin, D C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-9ad09ae7bbc14c4b730a440dbcc0da70be2ce3566c9c36c1d9376cbcafd378b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Attitude to Health</topic><topic>Biological and medical sciences</topic><topic>Costs and Cost Analysis</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Demography</topic><topic>Female</topic><topic>Health Status</topic><topic>Health Surveys</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Interviews as Topic</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Massachusetts</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple Sclerosis - diagnosis</topic><topic>Multiple Sclerosis - economics</topic><topic>Multiple Sclerosis - therapy</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Neurology</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Minden, S L</creatorcontrib><creatorcontrib>Frankel, D</creatorcontrib><creatorcontrib>Hadden, L</creatorcontrib><creatorcontrib>Perloff, J</creatorcontrib><creatorcontrib>Srinath, K P</creatorcontrib><creatorcontrib>Hoaglin, D C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Minden, S L</au><au>Frankel, D</au><au>Hadden, L</au><au>Perloff, J</au><au>Srinath, K P</au><au>Hoaglin, D C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2006-02-01</date><risdate>2006</risdate><volume>12</volume><issue>1</issue><spage>24</spage><epage>38</epage><pages>24-38</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><coden>MUSCFZ</coden><abstract>The Sonya Slifka Longitudinal Multiple Sclerosis Study follows a population-based cohort of approximately 2000 people with multiple sclerosis (MS) to study demographic and clinical characteristics, course of illness, utilization and cost of health services, provider characteristics, use of MS specialists and disease modifying agents, and neurologic, economic and psychosocial outcomes. This report describes the study methodology, presents baseline demographic and clinical data, and evaluates the representativeness of the sample. A stratified random sample of persons with established and recently-diagnosed MS selected from the National Multiple Sclerosis Society (NMSS) mailing lists was supplemented with recently-diagnosed patients recruited through systematic nationwide outreach. Baseline data were collected by computer-assisted telephone interviews derived from standardized instruments; data collection continues at six-month intervals. The cohort was comparable to population-based and clinical samples with respect to demographics, course, relapse rate, symptoms, and severity of disability. Almost two-thirds of the cohort needed help with activities of daily living, three-quarters were limited in work or other activities, and half had emotional problems that compromised quality of life. The Slifka Study cohort is broadly representative of the MS population and the database can be used to address questions not answered by natural history studies, clinical databases, or population-based surveys.</abstract><cop>Thousand Oaks, CA</cop><pub>SAGE Publications</pub><pmid>16459717</pmid><doi>10.1191/135248506ms1262oa</doi><tpages>15</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1352-4585 |
ispartof | Multiple sclerosis, 2006-02, Vol.12 (1), p.24-38 |
issn | 1352-4585 1477-0970 |
language | eng |
recordid | cdi_proquest_miscellaneous_67635013 |
source | Access via SAGE; MEDLINE |
subjects | Adolescent Adult Aged Aged, 80 and over Attitude to Health Biological and medical sciences Costs and Cost Analysis Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Demography Female Health Status Health Surveys Humans Immunomodulators Interviews as Topic Longitudinal Studies Male Massachusetts Medical sciences Middle Aged Multiple Sclerosis - diagnosis Multiple Sclerosis - economics Multiple Sclerosis - therapy Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Neurology Pharmacology. Drug treatments |
title | The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T11%3A22%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Sonya%20Slifka%20Longitudinal%20Multiple%20Sclerosis%20Study:%20methods%20and%20sample%20characteristics&rft.jtitle=Multiple%20sclerosis&rft.au=Minden,%20S%20L&rft.date=2006-02-01&rft.volume=12&rft.issue=1&rft.spage=24&rft.epage=38&rft.pages=24-38&rft.issn=1352-4585&rft.eissn=1477-0970&rft.coden=MUSCFZ&rft_id=info:doi/10.1191/135248506ms1262oa&rft_dat=%3Cproquest_cross%3E970002711%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218820539&rft_id=info:pmid/16459717&rft_sage_id=10.1191_135248506ms1262oa&rfr_iscdi=true |